소변 내 류코트리엔 농도에 따른 천식 환자들의 표현형 비교

키워드

참고문헌 (42)

1. Reddel HK, "Global Initiative for Asthma Strategy 2021 : executive summary and rationale for key changes", Eur Respir J, 31, pp.59~ (2021)
2. Kay AB, "Allergy and allergic diseases", Second of two parts. N Engl J Med, 344, pp.109~113 (2001)
3. Holgate ST, "The sentinel role of the airway epithelium in asthma pathogenesis", Immunol Rev, 242, pp.205~219 (2011)
4. Divekar R, "Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity", J Allergy Clin Immunol Pract, 4, pp.665~670 (2016)
5. Lee CW, "Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes", Immunology, 48, pp.27~35 (1983)
6. Laidlaw TM, "Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes", Blood, 119, pp.3790~3798 (2012)
7. Kolmert J, "Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. A clinical observational study", Am J Respir Crit Care Med, 203, pp.37~53 (2021)
8. Bankova LG, "A new spin on mast cells and cysteinyl leukotrienes : leukotriene E4 activates mast cells in vivo", J Allergy Clin Immunol, 142, pp.1056~1057 (2018)
9. Yoshihide Kanaoka, "Cysteinyl Leukotrienes and Their Receptors; Emerging Concepts", Allergy, Asthma & Immunology Research, 6(4), pp.288~295 (2014), 대한천식알레르기학회
10. Bossé Y, "Leukotriene D4-induced, epithelial cell-derived transforming growth factor β1 in human bronchial smooth muscle cell proliferation", Clin Exp Allergy, 38, pp.113~121 (2008)
11. Altraja S, "Proteome changes of human bronchial epithelial cells in response to pro-inflammatory mediator leukotriene E4 and pro-remodelling factor TGF-β1", J Proteomics, 73, pp.1230~1240 (2010)
12. Reiss TF, "Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma : a multicenter, randomized, double-blind trial", Arch Intern Med, 158, pp.1213~1220 (1998)
13. Choby G, "Urine leukotriene E4 : implications as a biomarker in chronic rhinosinusitis", Otolaryngol Head Neck Surg, 166, pp.224~232 (2022)
14. Hoffman BC, "Urinary leukotriene E4 as a biomarker of exposure, susceptibility, and risk in asthma : an update", Immunol Allergy Clin North Am, 38, pp.599~610 (2018)
15. Kumlin M, "Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics", Am Rev Respir Dis, 146, pp.96~103 (1992)
16. Kumlin M, "Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans", Clin Exp Allergy, 25, pp.467~479 (1995)
17. 최영우, "Which Factors Associated With Activated Eosinophils Contribute to the Pathogenesis of Aspirin-Exacerbated Respiratory Disease?", Allergy, Asthma & Immunology Research, 11(3), pp.320~329 (2019), 대한천식알레르기학회
18. Narayanankutty A, "Biochemical pathogenesis of aspirin exacerbated respiratory disease(AERD)", Clin Biochem, 46, pp.566~578 (2013)
19. Christie PE, "Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects", Am Rev Respir Dis, 143, pp.1025~1029 (1991)
20. Ban GY, "Persistent eosinophilic inflammation in adult asthmatics with high serum and urine levels of leukotriene E4", J Asthma Allergy, 14, pp.1219~1230 (2021)
21. Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2022, pp.59, 1362020~
22. Ban GY, "Association of eosinophil-derived neurotoxin levels with asthma control status in patients with aspirin-exacerbated respiratory disease", Clin Transl Allergy, 13, pp.e12229~ (2023)
23. Szefler SJ, "Asthma outcomes : biomarkers", J Allergy Clin Immunol, 129, pp.9~23 (2012)
24. Walgama ES, "Aspirin-exacerbated respiratory disease", Otolaryngol Clin North Am, 50, pp.83~94 (2017)
25. Ban GY, "Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease", Clin Exp Allergy, 47, pp.37~47 (2017)
26. Bochenek G, "Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma", J Allergy Clin Immunol Pract, 6, pp.528~535 (2018)
27. Marquette M, "Urinary leukotriene E4 as a biomarker in NSAID-exacerbated respiratory disease(N-ERD) : a systematic review and meta-analysis", Curr Allergy Asthma Rep, 22, pp.209~229 (2022)
28. Thorwarth RM, "Machine learning of biomarkers and clinical observation to predict eosinophilic chronic rhinosinusitis : a pilot study", Int Forum Allergy Rhinol, 11, pp.8~15 (2021)
29. Choby G, "Elevated urine leukotriene E4 is associated with worse objective markers in nasal polyposis patients", Laryngoscope, 131, pp.961~966 (2021)
30. Fitzpatrick AM, "Children with severe asthma have unique oxidative stress-associated metabolomic profiles", J Allergy Clin Immunol, 133, pp.258~261 (2014)
31. Green SA, "Increase in urinary leukotriene LTE4 levels in acute asthma : correlation with airflow limitation", Thorax, 59, pp.100~104 (2004)
32. Drazen JM, "Recovery of leukotriene E4 from the urine of patients with airway obstruction", Am Rev Respir Dis, 146, pp.104~108 (1992)
33. Reid GK, "Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis", J Biol Chem, 265, pp.19818~19823 (1990)
34. Rutten B, "Eosinophil-derived neurotoxin : a biologically and analytically attractive asthma biomarker", PLoS One, 16, pp.e0246627~ (2021)
35. Matsumoto H, "Serum periostin : a novel biomarker for asthma management", Allergol Int, 63, pp.153~160 (2014)
36. Wills-Karp M, "Interleukin-13 : central mediator of allergic asthma", Science, 282, pp.2258~2261 (1998)
37. Arima K, "IL-13", IL-13 receptor interaction, an emerging therapeutic target in allergic disease, 2005, pp.54, 229~233
38. Sidhu SS, "Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma", Proc Natl Acad Sci U S A, 107, pp.14170~14175 (2010)
39. Jia G, "Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients", J Allergy Clin Immunol, 130, pp.647~654 (2012)
40. Choi Y, "Immunomodulatory function of surfactant protein D in eosinophilic asthma", Allergy, 74, pp.192~195 (2019)
41. 반가영, "Plasma LTE4", PGF2α Ratio and Blood Eosinophil Count Are Increased in Elderly Asthmatics With Previous Asthma Exacerbation, 2017, pp.9(4), 378~382[DOI]
42. Dahlén SE, "Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist : a randomized, double-blind, placebo-controlled trial", Am J Respir Crit Care Med, 165, pp.9~14 (2002)

관련 논문AI추천